Regeneron Announces Investor Conference Presentations

TARRYTON, N.Y., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

• SVB Securities Global Biopharma Conference at 9:20 a.m. ET on Tuesday,
  February 14, 2023
  
  
• Cowen 43^rd Annual Health Care Conference at 12:50 p.m. ET on Monday,
  March 6, 2023
  
  
• Oppenheimer 33^rd Annual Healthcare Conference at 9:20 a.m. ET on Monday,
  March 13, 2023
  
  
• Barclays Global Healthcare Conference at 9:00 a.m. ET on Wednesday,
  March 15, 2023

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays of the webcasts will be archived on the Company's website for at least 30 days.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For more information, please visit www.Regeneron.com or follow @Regeneron on Twitter.

Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
[email protected]

You May Also Be Interested In

• Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
• Hi3D Launches First-Anniversary Campaign With Discounts, Creator Events and AI Tools for Custom 3D-Printed Football Figures
• North American Pet Insurance Adoption Continues to Grow as 7.6 Million Pet Parents Seek Peace of Mind